FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206572053> ?p ?o ?g. }

• W3206572053 endingPage "1364" @default.
• W3206572053 startingPage "1355" @default.
• W3206572053 abstract "Early discontinuation and poor adherence are common limitations of conventional preventive migraine medications that limit their long-term efficacy. Therefore, a migraine preventive medication with favorable long-term safety is warranted.This study aimed to evaluate the long-term safety and tolerability of fremanezumab for the preventive treatment of chronic or episodic migraine in Japanese patients.In this 52-week, randomized, open-label, parallel-group study, fremanezumab monthly or quarterly was administered in newly enrolled Japanese patients with chronic migraine or episodic migraine. Safety was assessed by monitoring of treatment-emergent adverse events, including injection-site reactions, laboratory and vital sign assessments. Newly enrolled patients and rollover patients from previous phase IIb/III trials who did not receive fremanezumab in this study were included in the immunogenicity testing cohort (n = 587). Efficacy outcomes included changes from baseline in the average monthly migraine days and headache days of at least moderate severity. Other efficacy outcomes included changes in disability scores.A total of 50 patients were enrolled with chronic migraine (monthly, n = 17; quarterly, n = 17) or episodic migraine (monthly, n = 8; quarterly, n = 8). The most commonly reported treatment-emergent adverse events were nasopharyngitis (64.0%) and injection-site reactions (erythema, 24.0%; induration, 10.0%; pain, 8.0%; pruritus, 6.0%). The discontinuation rate was low (4.0% from adverse events, 2.0% from a lack of efficacy) and no deaths were reported. The incidence of anti-drug antibody development was low (2.4%). Fremanezumab reduced monthly migraine days and headache days of at least moderate severity from 1 month after initial administration, and this effect was maintained with no worsening throughout 12 months. Fremanezumab also led to sustained reductions in any acute headache medication use and headache-related disability at 12 months.Fremanezumab administered monthly and quarterly was well tolerated in patients with chronic migraine and episodic migraine and led to sustained improvements in monthly migraine days and headache days of at least moderate severity throughout 12 months.ClinicalTrials.gov Identifier: NCT03303105." @default.
• W3206572053 created "2021-10-25" @default.
• W3206572053 creator A5005207942 @default.
• W3206572053 creator A5010975537 @default.
• W3206572053 creator A5011281487 @default.
• W3206572053 creator A5015541790 @default.
• W3206572053 creator A5021085198 @default.
• W3206572053 creator A5028184578 @default.
• W3206572053 creator A5055779548 @default.
• W3206572053 creator A5077638637 @default.
• W3206572053 date "2021-10-23" @default.
• W3206572053 modified "2023-10-08" @default.
• W3206572053 title "Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study" @default.
• W3206572053 cites W1491016423 @default.
• W3206572053 cites W2004916007 @default.
• W3206572053 cites W2005239637 @default.
• W3206572053 cites W204766049 @default.
• W3206572053 cites W2073160193 @default.
• W3206572053 cites W2132396249 @default.
• W3206572053 cites W2549116677 @default.
• W3206572053 cites W2746714361 @default.
• W3206572053 cites W2768357559 @default.
• W3206572053 cites W2801341258 @default.
• W3206572053 cites W2803715733 @default.
• W3206572053 cites W2910809224 @default.
• W3206572053 cites W2912442333 @default.
• W3206572053 cites W2918673304 @default.
• W3206572053 cites W2950645619 @default.
• W3206572053 cites W3084814300 @default.
• W3206572053 cites W3185467542 @default.
• W3206572053 cites W4214697113 @default.
• W3206572053 cites W4244823958 @default.
• W3206572053 cites W73775937 @default.
• W3206572053 doi "https://doi.org/10.1007/s40264-021-01119-2" @default.
• W3206572053 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8626354" @default.
• W3206572053 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34687446" @default.
• W3206572053 hasPublicationYear "2021" @default.
• W3206572053 type Work @default.
• W3206572053 sameAs 3206572053 @default.
• W3206572053 citedByCount "7" @default.
• W3206572053 countsByYear W32065720532022 @default.
• W3206572053 countsByYear W32065720532023 @default.
• W3206572053 crossrefType "journal-article" @default.
• W3206572053 hasAuthorship W3206572053A5005207942 @default.
• W3206572053 hasAuthorship W3206572053A5010975537 @default.
• W3206572053 hasAuthorship W3206572053A5011281487 @default.
• W3206572053 hasAuthorship W3206572053A5015541790 @default.
• W3206572053 hasAuthorship W3206572053A5021085198 @default.
• W3206572053 hasAuthorship W3206572053A5028184578 @default.
• W3206572053 hasAuthorship W3206572053A5055779548 @default.
• W3206572053 hasAuthorship W3206572053A5077638637 @default.
• W3206572053 hasBestOaLocation W32065720531 @default.
• W3206572053 hasConcept C126322002 @default.
• W3206572053 hasConcept C141071460 @default.
• W3206572053 hasConcept C187212893 @default.
• W3206572053 hasConcept C197934379 @default.
• W3206572053 hasConcept C207103383 @default.
• W3206572053 hasConcept C2778375690 @default.
• W3206572053 hasConcept C2778541695 @default.
• W3206572053 hasConcept C2778715236 @default.
• W3206572053 hasConcept C2780966972 @default.
• W3206572053 hasConcept C2910587157 @default.
• W3206572053 hasConcept C44249647 @default.
• W3206572053 hasConcept C71924100 @default.
• W3206572053 hasConceptScore W3206572053C126322002 @default.
• W3206572053 hasConceptScore W3206572053C141071460 @default.
• W3206572053 hasConceptScore W3206572053C187212893 @default.
• W3206572053 hasConceptScore W3206572053C197934379 @default.
• W3206572053 hasConceptScore W3206572053C207103383 @default.
• W3206572053 hasConceptScore W3206572053C2778375690 @default.
• W3206572053 hasConceptScore W3206572053C2778541695 @default.
• W3206572053 hasConceptScore W3206572053C2778715236 @default.
• W3206572053 hasConceptScore W3206572053C2780966972 @default.
• W3206572053 hasConceptScore W3206572053C2910587157 @default.
• W3206572053 hasConceptScore W3206572053C44249647 @default.
• W3206572053 hasConceptScore W3206572053C71924100 @default.
• W3206572053 hasFunder F4320324177 @default.
• W3206572053 hasIssue "12" @default.
• W3206572053 hasLocation W32065720531 @default.
• W3206572053 hasLocation W32065720532 @default.
• W3206572053 hasLocation W32065720533 @default.
• W3206572053 hasOpenAccess W3206572053 @default.
• W3206572053 hasPrimaryLocation W32065720531 @default.
• W3206572053 hasRelatedWork W2113717442 @default.
• W3206572053 hasRelatedWork W2792428998 @default.
• W3206572053 hasRelatedWork W2900121305 @default.
• W3206572053 hasRelatedWork W2937977035 @default.
• W3206572053 hasRelatedWork W2968435022 @default.
• W3206572053 hasRelatedWork W3038802552 @default.
• W3206572053 hasRelatedWork W3206572053 @default.
• W3206572053 hasRelatedWork W4200628345 @default.
• W3206572053 hasRelatedWork W4285278682 @default.
• W3206572053 hasRelatedWork W4379197173 @default.
• W3206572053 hasVolume "44" @default.
• W3206572053 isParatext "false" @default.
• W3206572053 isRetracted "false" @default.
• W3206572053 magId "3206572053" @default.
• W3206572053 workType "article" @default.